| Original language | English (US) |
|---|---|
| Pages (from-to) | 426 |
| Number of pages | 1 |
| Journal | Journal of Lower Genital Tract Disease |
| Volume | 24 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 1 2020 |
ASJC Scopus subject areas
- Obstetrics and Gynecology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Lower Genital Tract Disease, Vol. 24, No. 4, 01.10.2020, p. 426.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Response to Letter to the Editor Regarding
T2 - 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
AU - Perkins, Rebecca B.
AU - Guido, Richard L.
AU - Castle, Philip E.
AU - Chelmow, David
AU - Einstein, Mark H.
AU - Garcia, Francisco
AU - Huh, Warner K.
AU - Huh, Warner K.
AU - Kim, Jane J.
AU - Moscicki, Anna Barbara
AU - Nayar, Ritu
AU - Saraiya, Mona
AU - Sawaya, George
AU - Wentzensen, Nicolas
AU - Schiffman, Mark
N1 - Funding Information: The guidelines effort received support from the National Cancer Institute and the ASCCP. Participating organizations supported travel for their participating representatives. All participating consensus organizations, including the primary funders, had equal and balanced roles in the consensus process including data analysis and interpretation, writing of manuscript, and decision to submit for publication. No industry funds were used in the development of these guidelines. The corresponding authors had the final responsibility for the submission decision. M.S. and N.W. of the National Cancer Institute receive cervical screening results at reduced or no cost from commercial research partners (Qiagen, Roche, BD, MobileODT, Arbor Vita) for independent evaluations of screening methods and strategies. A-BM is an advisory board member of Merck and GSK. R.L.G. is on the Data Safety Monitoring Board for Inovio Pharmaceuticals and is an ASCCP consultant. W.K.H. is on the Data Safety Monitoring Board for Inovio Pharmaceuticals. P.E.C. has received HPV tests and assays at a reduced or no cost from Roche, Becton Dickinson, Arbor Vita Corporation, and Cepheid for research. M. H.E. has advised companies, participated in educational activities, but does not receive any honoraria or payments for these activities, In some cases, his employer, Rutgers, receives payment for his time for these activities from Papivax, Cynvec, Merck, Hologic, and PDS Biotechnologies. He has been the over-all principal investigator or local principal investigator for clinical trials from Johnson & Johnson, Pfizer, Iovance, and Inovio. Funding for these activities is for the research related costs of the trials. The other authors have declared they have no conflicts of interest. The conclusions, findings, and opinions expressed by the authors contributing to this journal do not necessarily reflect the official position of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the National Cancer Institute. R.B.P. and R.L.G. contributed equally to the development of this manuscript and are co-first authors.
PY - 2020/10/1
Y1 - 2020/10/1
UR - http://www.scopus.com/inward/record.url?scp=85091807044&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091807044&partnerID=8YFLogxK
U2 - 10.1097/LGT.0000000000000562
DO - 10.1097/LGT.0000000000000562
M3 - Letter
C2 - 32732648
AN - SCOPUS:85091807044
SN - 1089-2591
VL - 24
SP - 426
JO - Journal of Lower Genital Tract Disease
JF - Journal of Lower Genital Tract Disease
IS - 4
ER -